A Phase I/<scp>IB</scp>, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma
Authors
Noah M. Hahn (ORCID: https://orcid.org/0000-0002-1016-9024)
Heather Burney
Roberto Pili (ORCID: https://orcid.org/0009-0004-9993-9911)
David I. Quinn (ORCID: https://orcid.org/0000-0002-1411-0417)
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma
Noah M. Hahn, Heather Burney, Roberto Pili, David I. Quinn et al.
Citations
4 citations
Journal
Cancer Medicine
Topics
Renal cell carcinoma treatment
Field-Weighted Citation Impact (FWCI)
6.07
article
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial Carcinoma
Noah M. Hahn, Heather Burney, Roberto Pili, David I. Quinn, Sean Colligan, Nabil Adra, Theodore F. Logan
article en
4 citations
Abstract
No abstract available for this paper.
Publication Tag
Cancer MedicineVol. 14(7)
Institutions
Indiana University Health (US), Johns Hopkins University (US), USC Norris Comprehensive Cancer Center (US), Sidney Kimmel Comprehensive Cancer Center (US), Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University – Purdue University Indianapolis (US), University at Buffalo, State University of New York (US)